

News Release

Biofrontera AG Notice of Annual Results 2016

Leverkusen, Germany, 07 April 2016 - Biofrontera AG (AIM: B8F), the specialist for sun-induced skin cancer, will be announcing its financial results for the twelve-month period ended 31 December 2015 on 15 April 2016.

Conference calls for shareholders and interested investors will be held on 15 April 2016 at the following times:

*10.00am CET (4.00am EDT) conference call in German:
Dial-in number: +49-(0)69 271340800
Conference code: 96247638#*

*2.30pm CET (8.30am EDT) conference call in English:
Dial-in number Germany: +49-(0)69 271 340 801
Dial-in number UK: +44 203 36 45 807
Dial-in number USA: +1 240 64 50 345
Dial-in number USA (New York): +1 646 66 37 901
Conference code: 31292670#*

Ends

Enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
press@biofrontera.com
www.biofrontera.com

IR Germany: Brainwell Asset Solutions

Jürgen Benker

+49 (0) 152 08931514

IR UK: Seton Services

Toni Vallen

+44(0) 20 7603 6797

IR/Media US:

The Ruth Group

Lee Roth (Investors)

Kirsten Thomas (Media)

+1 646-536-7012
lroth@theruthgroup.com
+1 508-280-6592
kthomas@theruthgroup.com

Background:

The **Biofrontera Group** (FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz[®], a

News Release

prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz[®] to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos[®] dermatological range of cosmetics. Belixos[®] products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos[®] Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.